<DOC>
	<DOCNO>NCT00743847</DOCNO>
	<brief_summary>The primary objective protocol ass efficacy two dose strength varenicline ( 0.5 mg BID 1mg BID ) adjunctive treatment cognitive impairment symptomatically stable outpatient schizophrenic subject receive treatment atypical antipsychotic medication . A secondary objective evaluate safety tolerability two dos varenicline symptomatically stable schizophrenic subject receive treatment atypical antipsychotic medication .</brief_summary>
	<brief_title>A 6-Week Multicenter Trial Of Varenicline Tartrate For Cognitive Impairment In Subjects With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<criteria>Have current diagnosis schizophrenia Subjects must ongoing maintenance antipsychotic monotherapy combination therapy risperidone , olanzapine , quetiapine , ziprasidone , aripiprazole , paliperidone . Evidence stable symptomatology â‰¥3 month ( eg , hospitalization schizophrenia , increase level psychiatric care due worsen symptom schizophrenia ) . Subjects current DSMIV axis I diagnosis schizophrenia . Current treatment conventional antipsychotic ( e.g . fluphenazine , haloperidol ) clozapine , use adjunctive anticholinergic treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>schizophrenia , treatment , cognition</keyword>
</DOC>